Research graph
References from Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(16)30958-8
10.1016/s0140-6736(16)30958-8 · External reference
Photothermal Therapeutic Gold Nanoparticles Loaded with PD-L1 siRNA Enhanced Killing of NSCLC Cells by Immune Cells
10.2147/ijn.s518427 · 2025 · External reference
Targeting KMT5C Suppresses Lung Cancer Progression and Enhances the Efficacy of Immunotherapy
10.1002/advs.202407575 · 2025 · External reference
High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers
10.1038/s41419-025-07471-w · 2025 · External reference
10.1038/s41588-024-01998-y
10.1038/s41588-024-01998-y · External reference
Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion
10.1038/s41422-025-01205-5 · 2026 · External reference
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions
10.1186/s12943-025-02400-z · 2025 · External reference
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
10.1002/mco2.70274 · 2025 · External reference
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders
10.1016/j.ymthe.2024.09.026 · 2024 · External reference
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
10.1002/advs.202515403 · 2026 · External reference
Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming
10.1186/s40164-025-00719-3 · 2025 · External reference
The Multifaceted Pyruvate Metabolism: Role of the Mitochondrial Pyruvate Carrier
10.3390/biom10071068 · 2020 · External reference
Stem Cell Metabolism in Cancer and Healthy Tissues: Pyruvate in the Limelight
10.3389/fphar.2017.00958 · 2017 · External reference
10.1016/j.tibs.2016.01.002
10.1016/j.tibs.2016.01.002 · External reference
10.1038/s41568-025-00836-5
10.1038/s41568-025-00836-5 · External reference
10.1038/s41586-021-03442-1
10.1038/s41586-021-03442-1 · External reference
Myricetin prevents thapsigargin-induced CDK5-P66Shc signalosome mediated pancreatic β-cell dysfunction
10.1016/j.freeradbiomed.2019.05.038 · 2019 · External reference
10.4093/dmj.2024.0618
10.4093/dmj.2024.0618 · External reference
Optimised Workflows for Profiling the Metabolic Fluxes in Suspension vs. Adherent Cancer Cells via Seahorse Technology
10.3390/ijms26010154 · 2024 · External reference
Extracellular flux assay (Seahorse assay): Diverse applications in metabolic research across biological disciplines
10.1016/j.mocell.2024.100095 · 2024 · External reference
Evaluation of the Ligand-Independent Activation of a VHH-Based Anti-CD19 SynNotch Receptor by Dual-Luciferase Assay
10.1002/ansa.70046 · 2025 · External reference
10.1016/j.ymben.2020.11.002
10.1016/j.ymben.2020.11.002 · External reference
CUT&Tag reveals unconventional G-quadruplex landscape in Mycobacterium tuberculosis in response to oxidative stress
10.1038/s41467-025-62485-4 · 2025 · External reference
CUT&Tag overcomes biases of ChIP and establishes chromatin patterns for repetitive genomic loci
10.1016/j.isci.2025.113757 · 2025 · External reference
Pyruvate affects inflammatory responses of macrophages during influenza A virus infection
10.1016/j.virusres.2020.198088 · 2020 · External reference
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
10.1172/jci92167 · 2017 · External reference
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
10.3389/fphar.2023.1130937 · 2023 · External reference
Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer
10.1186/s12964-025-02498-0 · 2025 · External reference
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
10.1186/s13046-025-03519-z · 2025 · External reference
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
2024 · External reference
PD-1/PD-L1 Cancer Immunotherapeutics Reshape Tumor Microenvironment - Clinical Evidence and Molecular Mechanisms for AI-based Precision Medicine
10.1007/s12016-025-09105-7 · 2025 · External reference
Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1/PD-L1 Axis in the Tumor Microenvironment
10.7150/ijbs.104079 · 2025 · External reference
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
10.1016/j.esmoop.2025.104536 · 2025 · External reference
10.1016/j.cllc.2020.10.006
10.1016/j.cllc.2020.10.006 · External reference
Glutaminase inhibitor CB-839 causes metabolic adjustments in colorectal cancer cells
10.1038/s41598-025-20528-2 · 2025 · External reference
